ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stake Raised by Peregrine Capital Management LLC

Peregrine Capital Management LLC boosted its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 18.5% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 501,821 shares of the company's stock after purchasing an additional 78,260 shares during the quarter. Peregrine Capital Management LLC owned about 0.51% of ARS Pharmaceuticals worth $6,313,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of SPRY. Rhumbline Advisers increased its stake in shares of ARS Pharmaceuticals by 2.9% in the fourth quarter. Rhumbline Advisers now owns 65,163 shares of the company's stock valued at $687,000 after purchasing an additional 1,824 shares during the period. SBI Securities Co. Ltd. acquired a new position in shares of ARS Pharmaceuticals during the fourth quarter worth approximately $175,000. Steward Partners Investment Advisory LLC grew its holdings in ARS Pharmaceuticals by 47.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 38,050 shares of the company's stock worth $401,000 after buying an additional 12,200 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in ARS Pharmaceuticals by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 427,477 shares of the company's stock valued at $4,510,000 after acquiring an additional 3,530 shares during the period. Finally, Aigen Investment Management LP bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $216,000. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Price Performance

Shares of SPRY traded down $0.27 during midday trading on Friday, reaching $16.49. The stock had a trading volume of 881,491 shares, compared to its average volume of 1,340,395. ARS Pharmaceuticals, Inc. has a 52 week low of $8.86 and a 52 week high of $18.90. The company has a debt-to-equity ratio of 0.30, a current ratio of 11.00 and a quick ratio of 10.74. The firm's 50 day moving average price is $14.85 and its 200-day moving average price is $13.18. The company has a market capitalization of $1.62 billion, a P/E ratio of -103.02 and a beta of 0.90.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, meeting analysts' consensus estimates of ($0.35). The company had revenue of $7.97 million during the quarter, compared to the consensus estimate of $7.48 million. ARS Pharmaceuticals had a negative return on equity of 6.94% and a negative net margin of 16.11%. On average, analysts forecast that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, insider Alexander A. Fitzpatrick sold 102,969 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total transaction of $1,451,862.90. Following the sale, the insider owned 89,613 shares in the company, valued at $1,263,543.30. The trade was a 53.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Karas sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $16.99, for a total transaction of $254,850.00. Following the completion of the sale, the insider owned 10,315 shares of the company's stock, valued at approximately $175,251.85. This trade represents a 59.25% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,093,120 shares of company stock valued at $18,639,888 over the last 90 days. 33.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SPRY shares. Wall Street Zen raised ARS Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 28th. Scotiabank initiated coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 target price for the company. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $31.00.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.